Table 2. Average Values of Study Measures in those Participants Treated with AAPs & those Participants not Treated with AAPs.
Table 2 outlines the values of the various study measures investigated. Five broad columns are represented in this table. The first broad column lists the particular measures identified in the study. The second broad column lists the value for the particular measure averaged across the study participants who have not been treated with AAPs. The third broad column (with results of measures pertaining to those participants treated with AAPs) is further divided into six smaller columns. The first of these columns presents results of measures averaged across all participants treated with any AAP. The remaining five columns (one column for each specific AAP) each presents results from those participants receiving treatment with each respective AAP. The fourth broad column lists the value for the particular measure averaged across the entire study population. The fifth broad column provides results from statistical comparisons (Mann Whitney U testing for all variables with the exception of TNF-α where the Student’s T-Test was used) between those participants receiving AAP treatment and those not receiving AAP treatment. Significance reported for p < 0.05. Trend towards significance reported for 1.0 > p > 0.05.
| Study Measures | Not Treated with AAP | Treated with AAP | Total Population | Statistical Comparison (AAP Treatment vs. No AAP Treatment) | |||||
|---|---|---|---|---|---|---|---|---|---|
| All AAPs Included | Clozapine | Olanzepine | Quetiapine | Risperidone | Paliperidone | ||||
| Mean +/− SD (n = 53) | Mean +/− SD (n = 46) | Mean +/− SD (n = 3) | Mean +/− SD (n = 6) | Mean +/− SD (n = 27) | Mean +/− SD (n = 8) | Mean +/− SD (n = 4) | Mean +/− SD (n = 99) | ||
| Age (years) | 43.1 +/− 11.9 | 44.3 +/− 12.4 | 42.3 +/− 20.4 | 43.8 +/− 16.4 | 47.0 +/− 10.1 | 43.1 +/− 14.4 | 31.8 +/− 6.8 | 43.7 +/− 12.1 | P > 0.10 |
| TNF-α (pg/ml) | 8.6 +/− 2.4 | 9.9 +/− 2.2 | 10.1 +/− | 10.6 +/− 2.0 | 10.1 +/− 2.2 | 9.4 +/− 2.1 | 8.5 +/− 2.4 | 9.2 +/− 2.3 | T94=2.8, p = 0.005 (significant) |
| Mean Duration of Hospitalizations (months) | 0.6 +/− 1.3 | 0.5 +/− 0.7 | 0.4 +/− 0.3 | 0.3 +/− 0.2 | 0.5 +/− 0.8 | 0.6 +/− 0.7 | 0.2 +/− 0.1 | 0.5 +/− 1.0 | P > 0.10 |
| Age of Bipolar Diagnosis (years) | 30.1 +/− 11.3 | 32.2 +/− 11.5 | 36.0 +/− 18.7 | 27.7 +/− 8.7 | 35.2 +/− 11.3 | 29.3 +/− 12.5 | 25 +/− 8.6 | 31.1 +/− 11.4 | P > 0.10 |
| Number of Hospitalizations | 3.9 +/− 3.6 | 4.5 +/− 5.9 | 4.7 +/− 3.1 | 4.5 +/− 3.5 | 3.2 +/− 4.1 | 8.0 +/− 11.4 | 3.9 +/− 2.9 | 4.2 +/− 4.8 | P > 0.10 |
| Systolic BP (mm Hg) | 119.7 +/− 15.0 | 127.7 +/− 20.0 | 118.0 +/− 6.9 | 132.5 +/− 3.1 | 127.0 +/− 19.0 | 134.9 +/− 22.7 | 117.0 +/− 20.7 | 123.4 +/− 17.9 | Test Statistic = 2.0, P = 0.04 (significant) |
| Diastolic BP (mm Hg) | 70.0 +/− 10.2 | 77.5 +/− 11.4 | 71.0 +/− 10.4 | 76.5 +/− 7.1 | 78.3 +/− 12.6 | 86.1 +/− 59.4 | 70.3 +/− 12.4 | 73.5 +/− 11.4 | Test Statistic = 3.1, P = 0.002 (significant) |
| Waist Circumference (cm) | 102.4 +/− 17.2 | 102.7 +/− 17.2 | 90.7 +/− 4.7 | 105.0 +/− 17.9 | 104.1 +/− 17.2 | 108.5 +/− 16.6 | 90.0 +/− 16.8 | 102.5 +/− 17.2 | P > 0.10 |
| HDL (mg/dl) | 59.3 +/− 14.6 | 57.1 +/− 16.9 | 58.7 +/− 33.1 | 65.2 +/− 21.8 | 53.7 +/− 14.4 | 59.4 +/− 16.3 | 56.2 +/− 15.4 | 58.3 +/− 15.7 | P > 0.10 |
| Triglycerides (mg/dl) | 132.2 +/− 96.9 | 158.8 +/− 118.8 | 85.7 +/− 27.6 | 193.7 +/− 84.4 | 168.8 +/− 138.7 | 150.8 +/− 90.4 | 80.0 +/− 60.2 | 144.4 +/− 107.7 | P > 0.10 |
| Total Cholesterol (mg/dl) | 188.3 +/− 40.9 | 194.3 +/− 53.1 | 166.3 +/− 46.5 | 235.3 +/− 54.8 | 190.0 +/− 53.4 | 195.8 +/− 47.9 | 164.8 +/− 35.7 | 191.0 +/− 46.7 | P > 0.10 |
| Glucose (mg/dl) | 102.4 +/− 30.6 | 98.6 +/− 15.8 | 104.3 +/− 6.2 | 101.1 +/− 12.1 | 101.6 +/− 18.1 | 88.8 +/− 9.2 | 96.5 +/− 13.1 | 100.6 +/− 24.8 | P > 0.10 |